- $20.67m
- -$3.74m
- 14
- 38
- 22
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.86 | ||
| Price to Tang. Book | 0.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -98.76% | ||
| Return on Equity | -162.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Directors
- Terren Peizer CHM (62)
- Cuong Do PRE (55)
- Joanne Kim CFO
- Jonathan Adams EVP
- Clarence Ahlem EVP
- Penelope Markham EVP
- Christopher Reading EVP (65)
- Joseph Palumbo OTH
- Richard Berman IND (79)
- Steven Gorlin IND (84)
- Robert Hariri IND (62)
- James Lang IND (56)
- Sigmund Rogich IND (70)
- Michael Sherman IND (62)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 10th, 2013
- Public Since
- January 14th, 2014
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 18,451,981
- Address
- 680 W NYE LANE, SUITE 201, CARSON CITY, 89703
- Web
- https://www.bioviepharma.com/
- Phone
- +1 7758883162
- Auditors
- EisnerAmper LLP
Upcoming Events for BIVI
BioVie Inc Extraordinary Shareholders Meeting
Q4 2025 BioVie Inc Earnings Release
Q1 2026 BioVie Inc Earnings Release
Similar to BIVI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the BioVie share price?
As of Today at 19:37 UTC, shares in BioVie are trading at $1.12. This share price information is delayed by 15 minutes.
How has the BioVie share price performed this year?
Shares in BioVie last closed at $1.12 and the price had moved by -77.48% over the past 365 days. In terms of relative price strength the BioVie share price has underperformed the S&P500 Index by -79.22% over the past year.
What are the analyst and broker recommendations for BioVie?
The overall consensus recommendation for BioVie is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioVie dividend yield?
BioVie does not currently pay a dividend.
Does BioVie pay a dividend?
BioVie does not currently pay a dividend.
When does BioVie next pay dividends?
BioVie does not currently pay a dividend.
How do I buy BioVie shares?
To buy shares in BioVie you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioVie?
As of the previous close price of $1.12, shares in BioVie had a market capitalisation of $20.67m.
Where are BioVie shares listed?
Here are the trading details for BioVie:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BIVI
What kind of share is BioVie?
Based on an overall assessment of its quality, value and momentum BioVie is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioVie share price forecast for 2025?
The analyst consensus target price for shares in BioVie is $5.50. That is 391.07% above the last closing price of $1.12.
Analysts covering BioVie currently have a consensus Earnings Per Share (EPS) forecast of -$4.41 for the next financial year.
Find out moreWhat is the trend in the BioVie share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioVie. Over the past six months, its share price has underperformed the S&P500 Index by -56.82%.
As of the last closing price of $1.12, shares in BioVie were trading -45.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioVie PE Ratio?
The BioVie PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioVie?
BioVie's management team is headed by:
- Terren Peizer - CHM
- Cuong Do - PRE
- Joanne Kim - CFO
- Jonathan Adams - EVP
- Clarence Ahlem - EVP
- Penelope Markham - EVP
- Christopher Reading - EVP
- Joseph Palumbo - OTH
- Richard Berman - IND
- Steven Gorlin - IND
- Robert Hariri - IND
- James Lang - IND
- Sigmund Rogich - IND
- Michael Sherman - IND